ArticleAmerican journal of translational research2018
Application of real-time three-dimensional contrast-enhanced ultrasound using SonoVue for the evaluation of focal liver lesions: a prospective single-center study.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- [Ultrasound technology's new application in the diagnosis and treatment of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Demonstration of Hepatic Vein Abnormalities Using Contrast-Enhanced Sonography in Liver Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Contrast-Enhanced Sonography of the Liver: How to Avoid Artifacts.Diagnostics (Basel, Switzerland) · 2024Review
- Emerging contrast-enhanced ultrasound applications in children.Pediatric radiology · 2021Review
- Characteristics of hepatic solitary necrotic nodules on contrast-enhanced ultrasonography.BMC gastroenterology · 2021Article
- Editorial on "Role of thermal ablation in the management of colorectal liver metastasis".Hepatobiliary surgery and nutrition · 2020Article
- Comparison of Real-Time Two-Dimensional and Three-Dimensional Contrast-Enhanced Ultrasound to Quantify Flow in an In Vitro Model: A Feasibility Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal liver lesions (FLLs) include a variety of benign and malignant tumors, and are usually differential diagnosed by ultrasonography. However, traditional two-dimensional contrast-enhanced ultrasound (2D-CEUS) can evaluate a single slice of a lesion. It cannot fully display perfusion of a lesion and the relationship with the surrounding tissues, which may lead to misdiagnosis. This study aimed to investigate real-time three-dimensional CEUS (3D-CEUS) for evaluation of the vascular configuration of FLLs. Using real-time 3D-CEUS with SonoVue on 161 patients with FLLs, we found that when compared with 2D-CEUS, real-time 3D-CEUS provided more detailed information about the origin, continuity, and numbers and structures of the feeding artery. On 3D-CEUS hepatocellular carcinoma showed intratumoral vessels with diffuse enhancement, metastatic liver cancer showed peritumoral vessels or absence of tumor vessels with ring-like enhancement or non-enhancement, focal nodular hyperplasia showed a spoke-wheel artery with diffuse enhancement, and hemangiomas showed nodular enhancement. Our results demonstrate that real-time 3D-CEUS using SonoVue is an effective method for visualizing the characteristic vascular configuration of FLLs, and this may assist with the diagnosis.
Indexed as
Identifiers
29887960PMC5992562W3021443399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.